Navigation Links
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Date:11/7/2010

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.

"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.  "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."

ORAL Sequel (1024), an open label, follow-up Phase 2/3 study,
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
2. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
5. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
6. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
9. PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
10. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Aileron ... Summary Global Markets Direct,s, ,Aileron Therapeutics, ... an overview of the Aileron Therapeutics, Inc.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... -- According to their CEO, Rob Bohacs ... going through a complete transformation with highly targeted ... current clinical trial management process isn,t configured to ... which will ultimately drive the prescription cancer drugs ... been recognized by the National Cancer Institute as an ...
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... Dec. 6, 2011 Talyst, a leader in ... American Society of Health-System Pharmacists (ASHP) Midyear Clinical ... access and secure management of CII medications. AutoVault ... restocking of controlled substance inventory. AutoVault ...
... The report " Active Pharmaceutical Ingredient (API) Market ... analyzes and studies the major market drivers, restraints, and opportunities ... Rest of the world. Browse market ... Pharmaceutical Ingredient (API) Market Trends, Competitive Landscape and Global Forecasts ...
Cached Medicine Technology:Talyst Unveils AutoVault™ at ASHP 2011 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 2MarketsandMarkets: API Market is Expected to Reach $159.08 Billion by 2016 3
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... September 30, 2014 EverStryke , the ... introduction to SurvivalLife.com along with a free book and class ... of Shane Michaels, prompting an investigative review. , “Joe ... in the survival and preparation niche, and this product is ... great classes and survival products that Joe offers on his ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... plastic surgery providers in Turkey has gone up more ... of growth. The medical tourism company also reported total ... since October 2012. , The company’s professional strategy has ... in Turkey — ultimately designed for patient comfort and ...
Breaking Medicine News(10 mins):Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... researchers have found that yo-yo dieting can more than double ... dieting, also known as weight cycling, is a repeated loss ... ,Researchers studied 140,057 women aged between 50 and ... yo-yo dieting and compared women average waist size to those ...
... have found that symptoms in patients with obstructive sleep ... with nasal insufflation (TNI), using a nasal cannula ... rate. ,Our findings provide evidence that TNI ... obstructive hypopneas and apneas, said lead researcher Hartmut Schneider, ...
... Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly ... disease , but a new study finds that the ... be hospitalized for pneumonia. ,In a large ... inhaled corticosteroid use was associated with a significant 70 ...
... to open FatBurger fast food joint in Miami, Florida . ... South Beach diner revealed that she has been hooked to ... college. ,"That was part of my L.A. education ... all these low-riders (cars)... FatBurger was, like, the centrepiece for ...
... flowing in two of China's longest rivers -- the Yangtze ... change linked to the contraction of wetlands, warned the ... at the Chinese Academy of Sciences (CAS) as saying after ... wetlands on the Tibetan Plateau had shrunk by over 10 ...
... Actor/comedian Eddie Murphy is the worlds biggest love-rat, according to ... who has been named by Mel Bs pal Victoria Beckham ... callous way after she got pregnant with his child, topped ... Nutty Professor actor insisted on a DNA test to prove ...
Cached Medicine News:Health News:Nasal Cannula Treatment for Sleep Apnea Patients 2Health News:Nasal Cannula Treatment for Sleep Apnea Patients 3Health News:Patients Taking Inhaled Steroids may Develop Pneumonia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: